NCT03094416 - Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions

Hypothyroidism;Postablative

Interventions

DRUG

levothyroxine sodium capsule

after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in

DRUG

Proton pump inhibitor (PPI)

for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion

DRUG

Levothyroxine Sodium (LT4) Tablets

during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion

Trial Locations (9)

NYC Health + Hospitals/ Queens, New York

MedStar Union Memorial Hospital, Baltimore

Virginia Commonwealth University, Richmond

Diabetes & Endocrinology Consultants, PC, Morehead City

Carolina Ear Nose and Throat Clinic, Orangeburg

California Head and Neck Specialists, La Jolla

Coastal Metabolic Research Centre, Ventura

Stonesifer Endocrine Care & Clinical Research Inc., PS, Federal Way

Washington Hospital Center, Washington D.C.